Dexcom G6 CGM system receives CE mark for use in pregnancy

Dexcom announced that its Dexcom G6 continuous glucose monitoring (CGM) system received a further CE mark for use during pregnancy. The system, which is already indicated for patients with diabetes aged two years and older, now includes pregnant women with type 1, type 2 or gestational diabetes. The company noted that Dexcom G6 will be available for this new indication in the EU "soon," starting with the UK in the spring of 2020.

Erik Bjorkman, general manager and vice president for the company's EMEA division, remarked that "we are excited that the Dexcom G6 has received the CE mark in the EU for use during pregnancy. It is a life-changing development for this group of patients."  

The company noted that with the new indication, pregnant women with diabetes "can now have their CGM data readily available, which can help make their diabetes easier to manage." Meanwhile, the Dexcom G6 app allows patients to share their glucose information with up to five people, including their healthcare professional.

Did you like this article?